JP7370529B2 - 多能性幹細胞製造システム、幹細胞の誘導方法、幹細胞の浮遊培養方法、幹細胞の浮遊培養器、人工多能性幹細胞の作製方法、及び動物細胞から特定の体細胞を作製する方法 - Google Patents
多能性幹細胞製造システム、幹細胞の誘導方法、幹細胞の浮遊培養方法、幹細胞の浮遊培養器、人工多能性幹細胞の作製方法、及び動物細胞から特定の体細胞を作製する方法 Download PDFInfo
- Publication number
- JP7370529B2 JP7370529B2 JP2018510722A JP2018510722A JP7370529B2 JP 7370529 B2 JP7370529 B2 JP 7370529B2 JP 2018510722 A JP2018510722 A JP 2018510722A JP 2018510722 A JP2018510722 A JP 2018510722A JP 7370529 B2 JP7370529 B2 JP 7370529B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- medium
- cell
- ips
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000130 stem cell Anatomy 0.000 title claims description 252
- 238000000034 method Methods 0.000 title claims description 146
- 210000001082 somatic cell Anatomy 0.000 title claims description 120
- 230000001939 inductive effect Effects 0.000 title claims description 81
- 238000004519 manufacturing process Methods 0.000 title description 107
- 238000004114 suspension culture Methods 0.000 title description 78
- 210000004102 animal cell Anatomy 0.000 title description 58
- 210000004263 induced pluripotent stem cell Anatomy 0.000 title description 38
- 210000001778 pluripotent stem cell Anatomy 0.000 title description 3
- 239000002609 medium Substances 0.000 claims description 465
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 111
- 239000000725 suspension Substances 0.000 claims description 42
- 229920002148 Gellan gum Polymers 0.000 claims description 37
- 239000000216 gellan gum Substances 0.000 claims description 35
- 235000010492 gellan gum Nutrition 0.000 claims description 35
- 239000003102 growth factor Substances 0.000 claims description 29
- 239000001963 growth medium Substances 0.000 claims description 24
- 230000008569 process Effects 0.000 claims description 7
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims 4
- 210000004027 cell Anatomy 0.000 description 837
- 239000000499 gel Substances 0.000 description 230
- 239000000243 solution Substances 0.000 description 173
- 238000000502 dialysis Methods 0.000 description 111
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 107
- 108020004999 messenger RNA Proteins 0.000 description 104
- 229920002477 rna polymer Polymers 0.000 description 103
- 238000001638 lipofection Methods 0.000 description 81
- 210000005087 mononuclear cell Anatomy 0.000 description 68
- 230000008672 reprogramming Effects 0.000 description 60
- 239000007788 liquid Substances 0.000 description 57
- 238000000926 separation method Methods 0.000 description 51
- 210000000601 blood cell Anatomy 0.000 description 50
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 45
- 239000002953 phosphate buffered saline Substances 0.000 description 45
- 239000000411 inducer Substances 0.000 description 43
- 210000004369 blood Anatomy 0.000 description 42
- 239000008280 blood Substances 0.000 description 42
- 239000003112 inhibitor Substances 0.000 description 42
- 230000007246 mechanism Effects 0.000 description 39
- 108090000623 proteins and genes Proteins 0.000 description 39
- 239000003153 chemical reaction reagent Substances 0.000 description 38
- 239000011435 rock Substances 0.000 description 34
- 239000000203 mixture Substances 0.000 description 31
- -1 poly(glycerol monomethacrylate) Polymers 0.000 description 31
- 239000006285 cell suspension Substances 0.000 description 28
- 238000012258 culturing Methods 0.000 description 28
- 238000004806 packaging method and process Methods 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 26
- 238000005119 centrifugation Methods 0.000 description 24
- 230000006698 induction Effects 0.000 description 24
- 239000000872 buffer Substances 0.000 description 23
- 239000006228 supernatant Substances 0.000 description 23
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 22
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 22
- 238000005516 engineering process Methods 0.000 description 22
- 210000000653 nervous system Anatomy 0.000 description 22
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 20
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 20
- 239000000853 adhesive Substances 0.000 description 20
- 230000001070 adhesive effect Effects 0.000 description 20
- 230000004069 differentiation Effects 0.000 description 20
- 239000005090 green fluorescent protein Substances 0.000 description 20
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 20
- 238000002054 transplantation Methods 0.000 description 20
- 210000001744 T-lymphocyte Anatomy 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- 239000000126 substance Substances 0.000 description 17
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 16
- 230000003203 everyday effect Effects 0.000 description 16
- 239000013598 vector Substances 0.000 description 16
- 101150023320 B16R gene Proteins 0.000 description 15
- 101100316831 Vaccinia virus (strain Copenhagen) B18R gene Proteins 0.000 description 15
- 101100004099 Vaccinia virus (strain Western Reserve) VACWR200 gene Proteins 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 241000700605 Viruses Species 0.000 description 14
- 239000007789 gas Substances 0.000 description 14
- 238000001890 transfection Methods 0.000 description 14
- 241001430294 unidentified retrovirus Species 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 102000053602 DNA Human genes 0.000 description 13
- 241000713666 Lentivirus Species 0.000 description 13
- 102100038554 Neurogenin-2 Human genes 0.000 description 13
- 239000012124 Opti-MEM Substances 0.000 description 13
- 210000002950 fibroblast Anatomy 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 12
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 12
- 238000007667 floating Methods 0.000 description 12
- 229920000642 polymer Polymers 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 11
- 239000012528 membrane Substances 0.000 description 11
- 108091006146 Channels Proteins 0.000 description 10
- 230000002776 aggregation Effects 0.000 description 10
- 238000004220 aggregation Methods 0.000 description 10
- 239000006143 cell culture medium Substances 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 238000004520 electroporation Methods 0.000 description 10
- 229950010131 puromycin Drugs 0.000 description 10
- 239000012096 transfection reagent Substances 0.000 description 10
- 241000288906 Primates Species 0.000 description 9
- 229920002678 cellulose Polymers 0.000 description 9
- 238000005138 cryopreservation Methods 0.000 description 9
- 206010059866 Drug resistance Diseases 0.000 description 8
- 229910002092 carbon dioxide Inorganic materials 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 238000007710 freezing Methods 0.000 description 8
- 230000008014 freezing Effects 0.000 description 8
- 229920000609 methyl cellulose Polymers 0.000 description 8
- 239000001923 methylcellulose Substances 0.000 description 8
- 229920002883 poly(2-hydroxypropyl methacrylate) Polymers 0.000 description 8
- 229920003213 poly(N-isopropyl acrylamide) Polymers 0.000 description 8
- 229920002189 poly(glycerol 1-O-monomethacrylate) polymer Polymers 0.000 description 8
- 230000003362 replicative effect Effects 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 description 7
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 7
- 229930185560 Pseudouridine Natural products 0.000 description 7
- PTJWIQPHWPFNBW-UHFFFAOYSA-N Pseudouridine C Natural products OC1C(O)C(CO)OC1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-UHFFFAOYSA-N 0.000 description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
- 102000004142 Trypsin Human genes 0.000 description 7
- 108090000631 Trypsin Proteins 0.000 description 7
- WGDUUQDYDIIBKT-UHFFFAOYSA-N beta-Pseudouridine Natural products OC1OC(CN2C=CC(=O)NC2=O)C(O)C1O WGDUUQDYDIIBKT-UHFFFAOYSA-N 0.000 description 7
- 230000030833 cell death Effects 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- PTJWIQPHWPFNBW-GBNDHIKLSA-N pseudouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1C1=CNC(=O)NC1=O PTJWIQPHWPFNBW-GBNDHIKLSA-N 0.000 description 7
- 239000012588 trypsin Substances 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
- 101001094700 Homo sapiens POU domain, class 5, transcription factor 1 Proteins 0.000 description 6
- 101000713275 Homo sapiens Solute carrier family 22 member 3 Proteins 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 108020004459 Small interfering RNA Proteins 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 6
- 229940127219 anticoagulant drug Drugs 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 230000005757 colony formation Effects 0.000 description 6
- 238000011109 contamination Methods 0.000 description 6
- 238000007876 drug discovery Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 6
- 229920000669 heparin Polymers 0.000 description 6
- 229960002897 heparin Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 239000004055 small Interfering RNA Substances 0.000 description 6
- 239000013589 supplement Substances 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 230000007723 transport mechanism Effects 0.000 description 6
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 5
- 101000984042 Homo sapiens Protein lin-28 homolog A Proteins 0.000 description 5
- 102100025460 Protein lin-28 homolog A Human genes 0.000 description 5
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 5
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 5
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 5
- 108010076089 accutase Proteins 0.000 description 5
- 210000002469 basement membrane Anatomy 0.000 description 5
- 230000003749 cleanliness Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 239000012737 fresh medium Substances 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 description 4
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 4
- VKKXEIQIGGPMHT-UHFFFAOYSA-N 7h-purine-2,8-diamine Chemical compound NC1=NC=C2NC(N)=NC2=N1 VKKXEIQIGGPMHT-UHFFFAOYSA-N 0.000 description 4
- 239000012099 Alexa Fluor family Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108091028690 C-myc mRNA Proteins 0.000 description 4
- 229920001287 Chondroitin sulfate Polymers 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 241000283074 Equus asinus Species 0.000 description 4
- 229920000855 Fucoidan Polymers 0.000 description 4
- 229920002971 Heparan sulfate Polymers 0.000 description 4
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 4
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 4
- 229920002230 Pectic acid Polymers 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 239000000679 carrageenan Substances 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 229940113118 carrageenan Drugs 0.000 description 4
- 229920002301 cellulose acetate Polymers 0.000 description 4
- 229940059329 chondroitin sulfate Drugs 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 229920000591 gum Polymers 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 239000012533 medium component Substances 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 238000012806 monitoring device Methods 0.000 description 4
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 description 4
- 238000004091 panning Methods 0.000 description 4
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 4
- 239000001814 pectin Substances 0.000 description 4
- 229920001277 pectin Polymers 0.000 description 4
- 235000010987 pectin Nutrition 0.000 description 4
- 229920003175 pectinic acid Polymers 0.000 description 4
- 229920001507 poly(N-isopropylacrylamide-co-acrylamide) Polymers 0.000 description 4
- 229920001504 poly(N-isopropylacrylamide-co-acrylic acid) Polymers 0.000 description 4
- 229920001487 poly(N-isopropylacrylamide-co-butylacrylate) Polymers 0.000 description 4
- 229920001511 poly(N-isopropylacrylamide-co-methacrylic acid-co-octadecyl acrylate) Polymers 0.000 description 4
- 239000010318 polygalacturonic acid Substances 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000004627 regenerated cellulose Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- QQQSFSZALRVCSZ-UHFFFAOYSA-N triethoxysilane Chemical compound CCO[SiH](OCC)OCC QQQSFSZALRVCSZ-UHFFFAOYSA-N 0.000 description 4
- 239000001226 triphosphate Substances 0.000 description 4
- 235000011178 triphosphate Nutrition 0.000 description 4
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 4
- 239000000230 xanthan gum Substances 0.000 description 4
- 229920001285 xanthan gum Polymers 0.000 description 4
- 235000010493 xanthan gum Nutrition 0.000 description 4
- 229940082509 xanthan gum Drugs 0.000 description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 4
- 241000710929 Alphavirus Species 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102100041002 Forkhead box protein H1 Human genes 0.000 description 3
- 101000892840 Homo sapiens Forkhead box protein H1 Proteins 0.000 description 3
- 101001139134 Homo sapiens Krueppel-like factor 4 Proteins 0.000 description 3
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 description 3
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 description 3
- 101000984033 Homo sapiens Protein lin-28 homolog B Proteins 0.000 description 3
- 101000687905 Homo sapiens Transcription factor SOX-2 Proteins 0.000 description 3
- 101000857270 Homo sapiens Zinc finger protein GLIS1 Proteins 0.000 description 3
- 108010002386 Interleukin-3 Proteins 0.000 description 3
- 102100020677 Krueppel-like factor 4 Human genes 0.000 description 3
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 101710096140 Neurogenin-2 Proteins 0.000 description 3
- 102100025459 Protein lin-28 homolog B Human genes 0.000 description 3
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 3
- 101150086694 SLC22A3 gene Proteins 0.000 description 3
- 108010048349 Steroidogenic Factor 1 Proteins 0.000 description 3
- 102100029856 Steroidogenic factor 1 Human genes 0.000 description 3
- 102100024270 Transcription factor SOX-2 Human genes 0.000 description 3
- 108090000704 Tubulin Proteins 0.000 description 3
- 102000004243 Tubulin Human genes 0.000 description 3
- 102100025883 Zinc finger protein GLIS1 Human genes 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 238000004115 adherent culture Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 239000012997 ficoll-paque Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 108091072810 miR-294 stem-loop Proteins 0.000 description 3
- 210000003061 neural cell Anatomy 0.000 description 3
- 230000004031 neuronal differentiation Effects 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 229920001501 poly(N-isopropylacrylamide-co-methacrylic acid) Polymers 0.000 description 3
- 108010057417 polysialyl neural cell adhesion molecule Proteins 0.000 description 3
- 230000001172 regenerating effect Effects 0.000 description 3
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- XTJPMALIPQWXDY-KQYNXXCUSA-N (2r,3r,4s,5r)-2-[2-amino-6-(methylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(NC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O XTJPMALIPQWXDY-KQYNXXCUSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- MZBPLEJIMYNQQI-JXOAFFINSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2,4-dioxopyrimidine-5-carbaldehyde Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(C=O)=C1 MZBPLEJIMYNQQI-JXOAFFINSA-N 0.000 description 2
- UVBYMVOUBXYSFV-XUTVFYLZSA-N 1-methylpseudouridine Chemical compound O=C1NC(=O)N(C)C=C1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 UVBYMVOUBXYSFV-XUTVFYLZSA-N 0.000 description 2
- SXUXMRMBWZCMEN-UHFFFAOYSA-N 2'-O-methyl uridine Natural products COC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-UHFFFAOYSA-N 0.000 description 2
- SXUXMRMBWZCMEN-ZOQUXTDFSA-N 2'-O-methyluridine Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 SXUXMRMBWZCMEN-ZOQUXTDFSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- SVRWPYGLQBPNNJ-UAKXSSHOSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidine-5-carboxylic acid Chemical compound C1=C(C(O)=O)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 SVRWPYGLQBPNNJ-UAKXSSHOSA-N 0.000 description 2
- MPPUDRFYDKDPBN-UAKXSSHOSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxypyrimidin-2-one Chemical compound C1=C(O)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 MPPUDRFYDKDPBN-UAKXSSHOSA-N 0.000 description 2
- NFEXJLMYXXIWPI-JXOAFFINSA-N 5-Hydroxymethylcytidine Chemical compound C1=C(CO)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NFEXJLMYXXIWPI-JXOAFFINSA-N 0.000 description 2
- VQAJJNQKTRZJIQ-JXOAFFINSA-N 5-Hydroxymethyluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(CO)=C1 VQAJJNQKTRZJIQ-JXOAFFINSA-N 0.000 description 2
- ZXIATBNUWJBBGT-JXOAFFINSA-N 5-methoxyuridine Chemical compound O=C1NC(=O)C(OC)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZXIATBNUWJBBGT-JXOAFFINSA-N 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 2
- 208000031404 Chromosome Aberrations Diseases 0.000 description 2
- 102100037124 Developmental pluripotency-associated 5 protein Human genes 0.000 description 2
- 102100036949 Developmental pluripotency-associated protein 2 Human genes 0.000 description 2
- 102100037126 Developmental pluripotency-associated protein 4 Human genes 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102100037362 Fibronectin Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 2
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 2
- 102100037060 Forkhead box protein D3 Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 2
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 2
- 101000881848 Homo sapiens Developmental pluripotency-associated 5 protein Proteins 0.000 description 2
- 101000804948 Homo sapiens Developmental pluripotency-associated protein 2 Proteins 0.000 description 2
- 101000881868 Homo sapiens Developmental pluripotency-associated protein 4 Proteins 0.000 description 2
- 101001029308 Homo sapiens Forkhead box protein D3 Proteins 0.000 description 2
- 101001139130 Homo sapiens Krueppel-like factor 5 Proteins 0.000 description 2
- 101000603698 Homo sapiens Neurogenin-2 Proteins 0.000 description 2
- 101000603323 Homo sapiens Nuclear receptor subfamily 0 group B member 1 Proteins 0.000 description 2
- 101001109685 Homo sapiens Nuclear receptor subfamily 5 group A member 2 Proteins 0.000 description 2
- 101000958664 Homo sapiens Nucleus accumbens-associated protein 1 Proteins 0.000 description 2
- 101000740204 Homo sapiens Sal-like protein 2 Proteins 0.000 description 2
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 description 2
- 101000851696 Homo sapiens Steroid hormone receptor ERR2 Proteins 0.000 description 2
- 101000666775 Homo sapiens T-box transcription factor TBX3 Proteins 0.000 description 2
- 101000653679 Homo sapiens Translationally-controlled tumor protein Proteins 0.000 description 2
- 101000777245 Homo sapiens Undifferentiated embryonic cell transcription factor 1 Proteins 0.000 description 2
- 101000784538 Homo sapiens Zinc finger and SCAN domain-containing protein 10 Proteins 0.000 description 2
- 101000976622 Homo sapiens Zinc finger protein 42 homolog Proteins 0.000 description 2
- 101000976645 Homo sapiens Zinc finger protein ZIC 3 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102100020680 Krueppel-like factor 5 Human genes 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 2
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 2
- VQAYFKKCNSOZKM-IOSLPCCCSA-N N(6)-methyladenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O VQAYFKKCNSOZKM-IOSLPCCCSA-N 0.000 description 2
- ZBZXYUYUUDZCNB-UHFFFAOYSA-N N-cyclohexa-1,3-dien-1-yl-N-phenyl-4-[4-(N-[4-[4-(N-[4-[4-(N-phenylanilino)phenyl]phenyl]anilino)phenyl]phenyl]anilino)phenyl]aniline Chemical compound C1=CCCC(N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC(=CC=2)C=2C=CC(=CC=2)N(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 ZBZXYUYUUDZCNB-UHFFFAOYSA-N 0.000 description 2
- LZCNWAXLJWBRJE-ZOQUXTDFSA-N N4-Methylcytidine Chemical compound O=C1N=C(NC)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 LZCNWAXLJWBRJE-ZOQUXTDFSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000003729 Neprilysin Human genes 0.000 description 2
- 108090000028 Neprilysin Proteins 0.000 description 2
- 102100039019 Nuclear receptor subfamily 0 group B member 1 Human genes 0.000 description 2
- 102100022669 Nuclear receptor subfamily 5 group A member 2 Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 101001031368 Rattus norvegicus Histone H2A type 4 Proteins 0.000 description 2
- 102100037205 Sal-like protein 2 Human genes 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 description 2
- 102100036831 Steroid hormone receptor ERR2 Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102100038409 T-box transcription factor TBX3 Human genes 0.000 description 2
- 206010043276 Teratoma Diseases 0.000 description 2
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 2
- 102100029887 Translationally-controlled tumor protein Human genes 0.000 description 2
- 102100031278 Undifferentiated embryonic cell transcription factor 1 Human genes 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- 102100020919 Zinc finger and SCAN domain-containing protein 10 Human genes 0.000 description 2
- 102100023550 Zinc finger protein 42 homolog Human genes 0.000 description 2
- 102100023495 Zinc finger protein ZIC 3 Human genes 0.000 description 2
- FHHZHGZBHYYWTG-INFSMZHSSA-N [(2r,3s,4r,5r)-5-(2-amino-7-methyl-6-oxo-3h-purin-9-ium-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[[(2r,3s,4r,5r)-5-(2-amino-6-oxo-3h-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] phosphate Chemical group N1C(N)=NC(=O)C2=C1[N+]([C@H]1[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=C(C(N=C(N)N4)=O)N=C3)O)O1)O)=CN2C FHHZHGZBHYYWTG-INFSMZHSSA-N 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 229930189065 blasticidin Natural products 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 238000004555 blood preservation Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000003320 cell separation method Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 102000045835 human NEUROG2 Human genes 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 238000005459 micromachining Methods 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000012858 packaging process Methods 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 239000003761 preservation solution Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 108700029878 rat Neurog2 Proteins 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 229940045145 uridine Drugs 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- 238000004017 vitrification Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- LAQPKDLYOBZWBT-NYLDSJSYSA-N (2s,4s,5r,6r)-5-acetamido-2-{[(2s,3r,4s,5s,6r)-2-{[(2r,3r,4r,5r)-5-acetamido-1,2-dihydroxy-6-oxo-4-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-4-hydroxy-6-[(1r,2r)-1,2,3-trihydrox Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 LAQPKDLYOBZWBT-NYLDSJSYSA-N 0.000 description 1
- ODDDVFDZBGTKDX-VPCXQMTMSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-methyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1=CC(=O)NC(=O)N1[C@]1(C)O[C@H](CO)[C@@H](O)[C@H]1O ODDDVFDZBGTKDX-VPCXQMTMSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 241000178568 Aura virus Species 0.000 description 1
- 241000231314 Babanki virus Species 0.000 description 1
- 241000710946 Barmah Forest virus Species 0.000 description 1
- 241000608319 Bebaru virus Species 0.000 description 1
- 241000231316 Buggy Creek virus Species 0.000 description 1
- 101100257359 Caenorhabditis elegans sox-2 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920001747 Cellulose diacetate Polymers 0.000 description 1
- 229920002284 Cellulose triacetate Polymers 0.000 description 1
- 241001502567 Chikungunya virus Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 235000005956 Cosmos caudatus Nutrition 0.000 description 1
- 101001042415 Cratylia mollis Mannose/glucose-specific lectin Cramoll Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 241001453233 Doodia media Species 0.000 description 1
- 102100023196 E3 ubiquitin-protein ligase MARCHF8 Human genes 0.000 description 1
- 101710190174 E3 ubiquitin-protein ligase MYLIP Proteins 0.000 description 1
- 241000710945 Eastern equine encephalitis virus Species 0.000 description 1
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 1
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 102100029775 Eukaryotic translation initiation factor 1 Human genes 0.000 description 1
- 241000465885 Everglades virus Species 0.000 description 1
- 241000231322 Fort Morgan virus Species 0.000 description 1
- 241000608297 Getah virus Species 0.000 description 1
- 241000710948 Highlands J virus Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101001012787 Homo sapiens Eukaryotic translation initiation factor 1 Proteins 0.000 description 1
- 101001139146 Homo sapiens Krueppel-like factor 2 Proteins 0.000 description 1
- 101000643378 Homo sapiens Serine racemase Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100020675 Krueppel-like factor 2 Human genes 0.000 description 1
- 241000231318 Kyzylagach virus Species 0.000 description 1
- 241000608292 Mayaro virus Species 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 241000868135 Mucambo virus Species 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 101100257363 Mus musculus Sox2 gene Proteins 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 241000608287 Ndumu virus Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241000868134 Pixuna virus Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 241000710942 Ross River virus Species 0.000 description 1
- 241000608282 Sagiyama virus Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000608278 Una virus Species 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 241000231320 Whataroa virus Species 0.000 description 1
- 208000033451 X-linked combined immunodeficiency Diseases 0.000 description 1
- NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004887 air purification Methods 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- AIXMJTYHQHQJLU-UHFFFAOYSA-N chembl210858 Chemical compound O1C(CC(=O)OC)CC(C=2C=CC(O)=CC=2)=N1 AIXMJTYHQHQJLU-UHFFFAOYSA-N 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 231100000244 chromosomal damage Toxicity 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- ZURAKLKIKYCUJU-UHFFFAOYSA-N copper;azane Chemical compound N.[Cu+2] ZURAKLKIKYCUJU-UHFFFAOYSA-N 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 230000005860 defense response to virus Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 239000003219 hemolytic agent Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 108010038862 laminin 10 Proteins 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 101150033420 lmo2 gene Proteins 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 108091076076 miR-295 stem-loop Proteins 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052754 neon Inorganic materials 0.000 description 1
- GKAOGPIIYCISHV-UHFFFAOYSA-N neon atom Chemical compound [Ne] GKAOGPIIYCISHV-UHFFFAOYSA-N 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000005015 neuronal process Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000013441 quality evaluation Methods 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/48—Automatic or computerized control
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/28—Constructional details, e.g. recesses, hinges disposable or single use
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/44—Multiple separable units; Modules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M27/00—Means for mixing, agitating or circulating fluids in the vessel
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C12M29/04—Filters; Permeable or porous membranes or plates, e.g. dialysis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M37/00—Means for sterilizing, maintaining sterile conditions or avoiding chemical or biological contamination
- C12M37/02—Filters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/12—Means for regulation, monitoring, measurement or control, e.g. flow regulation of temperature
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M41/00—Means for regulation, monitoring, measurement or control, e.g. flow regulation
- C12M41/30—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration
- C12M41/36—Means for regulation, monitoring, measurement or control, e.g. flow regulation of concentration of biomass, e.g. colony counters or by turbidity measurements
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M45/00—Means for pre-treatment of biological substances
- C12M45/02—Means for pre-treatment of biological substances by mechanical forces; Stirring; Trituration; Comminuting
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/04—Cell isolation or sorting
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Sustainable Development (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Clinical Laboratory Science (AREA)
- Hematology (AREA)
- Computer Hardware Design (AREA)
- Physics & Mathematics (AREA)
- Thermal Sciences (AREA)
- Immunology (AREA)
- Mechanical Engineering (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019206125A JP7351483B2 (ja) | 2015-08-31 | 2019-11-14 | 多能性幹細胞製造システム、幹細胞の誘導方法、幹細胞の浮遊培養方法、幹細胞の浮遊培養器、人工多能性幹細胞の作製方法、及び動物細胞から特定の体細胞を作製する方法 |
| JP2022063287A JP2022088643A (ja) | 2015-08-31 | 2022-04-06 | 多能性幹細胞製造システム、幹細胞の誘導方法、幹細胞の浮遊培養方法、幹細胞の浮遊培養器、人工多能性幹細胞の作製方法、及び動物細胞から特定の体細胞を作製する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015170797 | 2015-08-31 | ||
| JP2015170797 | 2015-08-31 | ||
| US201662356199P | 2016-06-29 | 2016-06-29 | |
| US62/356,199 | 2016-06-29 | ||
| PCT/US2016/049530 WO2017040548A1 (en) | 2015-08-31 | 2016-08-30 | Pluripotent stem cell manufacturing system and method for producing induced pluripotent stem cells |
Related Child Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019206182A Division JP2020036608A (ja) | 2015-08-31 | 2019-11-14 | 多能性幹細胞製造システム、幹細胞の誘導方法、幹細胞の浮遊培養方法、幹細胞の浮遊培養器、人工多能性幹細胞の作製方法、及び動物細胞から特定の体細胞を作製する方法 |
| JP2019206125A Division JP7351483B2 (ja) | 2015-08-31 | 2019-11-14 | 多能性幹細胞製造システム、幹細胞の誘導方法、幹細胞の浮遊培養方法、幹細胞の浮遊培養器、人工多能性幹細胞の作製方法、及び動物細胞から特定の体細胞を作製する方法 |
| JP2022063287A Division JP2022088643A (ja) | 2015-08-31 | 2022-04-06 | 多能性幹細胞製造システム、幹細胞の誘導方法、幹細胞の浮遊培養方法、幹細胞の浮遊培養器、人工多能性幹細胞の作製方法、及び動物細胞から特定の体細胞を作製する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526992A JP2018526992A (ja) | 2018-09-20 |
| JP2018526992A5 JP2018526992A5 (enExample) | 2019-10-03 |
| JP7370529B2 true JP7370529B2 (ja) | 2023-10-30 |
Family
ID=58188066
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018510722A Active JP7370529B2 (ja) | 2015-08-31 | 2016-08-30 | 多能性幹細胞製造システム、幹細胞の誘導方法、幹細胞の浮遊培養方法、幹細胞の浮遊培養器、人工多能性幹細胞の作製方法、及び動物細胞から特定の体細胞を作製する方法 |
| JP2017526727A Active JP6198203B2 (ja) | 2015-08-31 | 2016-08-31 | 多能性幹細胞製造システム |
| JP2017097398A Active JP6283904B2 (ja) | 2015-08-31 | 2017-05-16 | 多能性幹細胞製造システム |
| JP2017097408A Pending JP2017221187A (ja) | 2015-08-31 | 2017-05-16 | 多能性幹細胞製造システム |
| JP2017155756A Active JP6253216B2 (ja) | 2015-08-31 | 2017-08-10 | 多能性幹細胞製造システム |
| JP2019206125A Active JP7351483B2 (ja) | 2015-08-31 | 2019-11-14 | 多能性幹細胞製造システム、幹細胞の誘導方法、幹細胞の浮遊培養方法、幹細胞の浮遊培養器、人工多能性幹細胞の作製方法、及び動物細胞から特定の体細胞を作製する方法 |
| JP2022063287A Pending JP2022088643A (ja) | 2015-08-31 | 2022-04-06 | 多能性幹細胞製造システム、幹細胞の誘導方法、幹細胞の浮遊培養方法、幹細胞の浮遊培養器、人工多能性幹細胞の作製方法、及び動物細胞から特定の体細胞を作製する方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526727A Active JP6198203B2 (ja) | 2015-08-31 | 2016-08-31 | 多能性幹細胞製造システム |
| JP2017097398A Active JP6283904B2 (ja) | 2015-08-31 | 2017-05-16 | 多能性幹細胞製造システム |
| JP2017097408A Pending JP2017221187A (ja) | 2015-08-31 | 2017-05-16 | 多能性幹細胞製造システム |
| JP2017155756A Active JP6253216B2 (ja) | 2015-08-31 | 2017-08-10 | 多能性幹細胞製造システム |
| JP2019206125A Active JP7351483B2 (ja) | 2015-08-31 | 2019-11-14 | 多能性幹細胞製造システム、幹細胞の誘導方法、幹細胞の浮遊培養方法、幹細胞の浮遊培養器、人工多能性幹細胞の作製方法、及び動物細胞から特定の体細胞を作製する方法 |
| JP2022063287A Pending JP2022088643A (ja) | 2015-08-31 | 2022-04-06 | 多能性幹細胞製造システム、幹細胞の誘導方法、幹細胞の浮遊培養方法、幹細胞の浮遊培養器、人工多能性幹細胞の作製方法、及び動物細胞から特定の体細胞を作製する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US11286454B2 (enExample) |
| EP (4) | EP3344755A4 (enExample) |
| JP (7) | JP7370529B2 (enExample) |
| CN (5) | CN114717183B (enExample) |
| CA (2) | CA2996582A1 (enExample) |
| SG (1) | SG11201801549VA (enExample) |
| WO (2) | WO2017040548A1 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114717183B (zh) | 2015-08-31 | 2024-11-29 | 爱平世股份有限公司 | 多能干细胞制造系统和生产诱导多能干细胞的方法 |
| EP3541922A4 (en) * | 2016-11-18 | 2020-06-03 | New York Stem Cell Foundation, Inc. | MICROFLUIDIC SYSTEM AND METHOD FOR USE THEREOF |
| JP6968104B2 (ja) | 2017-01-20 | 2021-11-17 | 富士フイルム株式会社 | 細胞培養装置及び細胞培養方法 |
| CA3054119A1 (en) | 2017-02-24 | 2018-08-30 | I Peace, Inc. | Cell treatment device, suspension culture vessel, and stem cell induction method |
| WO2018155595A1 (ja) * | 2017-02-24 | 2018-08-30 | 剛士 田邊 | 人工多能性幹細胞の作製方法 |
| SG11201907406WA (en) * | 2017-02-27 | 2019-09-27 | Koji Tanabe | Cell processing system and cell processing device |
| WO2018154788A1 (ja) * | 2017-02-27 | 2018-08-30 | 剛士 田邊 | 体細胞製造システム |
| NZ759234A (en) * | 2017-05-26 | 2022-12-23 | Kite Pharma Inc | Methods of making and using embryonic mesenchymal progenitor cells |
| WO2019040915A1 (en) * | 2017-08-24 | 2019-02-28 | Terumo Bct, Inc. | CELL EXPANSION |
| CA3074582A1 (en) * | 2017-09-08 | 2019-03-14 | Otsuka Pharmaceutical Factory, Inc. | Stem cell derived from neonatal pig and method for producing same |
| WO2019131626A1 (ja) * | 2017-12-28 | 2019-07-04 | オリンパス株式会社 | 細胞培養制御方法、細胞培養制御装置、細胞培養装置および細胞培養システム |
| US11932842B2 (en) | 2018-02-09 | 2024-03-19 | Global Life Sciences Solutions Usa Llc | Bioprocessing apparatus |
| US11920119B2 (en) | 2018-02-09 | 2024-03-05 | Global Life Sciences Solutions Usa Llc | Systems and methods for bioprocessing |
| US12077743B2 (en) | 2018-02-09 | 2024-09-03 | Global Life Sciences Solutions Usa Llc | Apparatus for fluid line management in a bioprocessing system |
| US12252682B2 (en) | 2018-02-09 | 2025-03-18 | Global Life Sciences Solutions Usa Llc | System and method for fluid flow management in a bioprocessing system |
| AU2019219295B2 (en) * | 2018-02-09 | 2024-07-11 | Global Life Sciences Solutions Usa Llc | Bioprocessing vessel |
| JP6939643B2 (ja) * | 2018-02-26 | 2021-09-22 | 株式会社Ihi | 細胞分割装置及び細胞培養装置 |
| CN112585257A (zh) * | 2018-06-19 | 2021-03-30 | 加拿大干细胞科技公司 | 用于细胞自动培养的系统、方法及装置 |
| WO2020017411A1 (ja) * | 2018-07-17 | 2020-01-23 | 国立大学法人神戸大学 | 固液界面検出装置及びこれを備えた前処理装置 |
| JPWO2020021860A1 (ja) * | 2018-07-24 | 2021-06-10 | 富士フイルム株式会社 | 細胞培養支援装置の作動プログラム、細胞培養支援装置、細胞培養支援装置の作動方法 |
| US20210198635A1 (en) * | 2018-08-20 | 2021-07-01 | I Peace, Inc. | Cell culture or induction method |
| JP7280574B2 (ja) * | 2018-08-20 | 2023-05-24 | アイ ピース，インコーポレイテッド | 細胞培養器 |
| WO2020044984A1 (ja) * | 2018-08-27 | 2020-03-05 | 富士フイルム株式会社 | 細胞培養方法及び細胞培養装置 |
| US20200248123A1 (en) | 2019-02-05 | 2020-08-06 | Corning Incorporated | Packed-bed bioreactor systems and methods of using the same |
| JP2020167959A (ja) * | 2019-04-04 | 2020-10-15 | オリンパス株式会社 | 培地モニタリング装置 |
| JP7416764B2 (ja) * | 2019-03-25 | 2024-01-17 | テルモ株式会社 | 細胞培養物を清浄度の高い空間において調製するための容器及びキット |
| JP7483687B2 (ja) * | 2019-03-27 | 2024-05-15 | 株式会社カネカ | 細胞製造装置、細胞製造方法並びにこれに用いられるサーバ、システムおよび装置 |
| CN110066733A (zh) * | 2019-05-29 | 2019-07-30 | 广东唯泰生物科技有限公司 | 干细胞培养机器人 |
| CN113785049B (zh) * | 2019-06-10 | 2025-11-25 | 爱平世股份有限公司 | 细胞培养方法及单核细胞的回收方法 |
| US20220234043A1 (en) * | 2019-06-28 | 2022-07-28 | I Peace, Inc. | Cell mass dissociator, method for manufacturing cell mass dissociator, and method for dissociating cell mass |
| EP3992277A4 (en) * | 2019-06-28 | 2023-10-04 | I Peace, Inc. | CELL CULTURE CONTAINER AND CELL CULTURE APPARATUS |
| CN110229751A (zh) * | 2019-07-17 | 2019-09-13 | 中国人民解放军军事科学院军事医学研究院 | mRNA制备系统及制备方法 |
| CN114341341A (zh) * | 2019-08-29 | 2022-04-12 | 发那科株式会社 | 细胞制造装置及其制造方法 |
| EP4410947A3 (en) * | 2019-08-29 | 2024-08-28 | Fanuc Corporation | Cell production device and system therefor |
| JP7297272B2 (ja) * | 2019-08-29 | 2023-06-26 | ファナック株式会社 | 細胞製造装置 |
| US11118151B2 (en) | 2019-11-05 | 2021-09-14 | Corning Incorporated | Fixed bed bioreactor and methods of using the same |
| WO2021090767A1 (ja) * | 2019-11-06 | 2021-05-14 | アイ ピース， インコーポレイテッド | 細胞培養装置 |
| CN111126329A (zh) * | 2019-12-30 | 2020-05-08 | 杭州原生生物科技有限公司 | 一种自动识别多能干细胞群的方法 |
| EP4108757A4 (en) * | 2020-02-21 | 2023-11-22 | I Peace, Inc. | SOLUTION TRANSPORT DEVICE |
| US20210363479A1 (en) * | 2020-05-22 | 2021-11-25 | Sqz Biotechnologies Company | Point of care system for automatically processing cells |
| CN111666895B (zh) * | 2020-06-08 | 2023-05-26 | 上海市同济医院 | 基于深度学习的神经干细胞分化方向预测系统及方法 |
| JP7682619B2 (ja) * | 2020-10-19 | 2025-05-26 | キヤノンメディカルシステムズ株式会社 | 誘導多能性幹細胞樹立装置及び方法 |
| EP4267713A4 (en) * | 2020-12-23 | 2025-03-05 | Cedars-Sinai Medical Center | METHOD FOR DIFFERENTIATION OF EXOCRINE PANCREAS CELLS FROM HUMAN INDUCED PLURIPOTENT STEM CELLS |
| JP7744155B2 (ja) * | 2021-04-19 | 2025-09-25 | キヤノンメディカルシステムズ株式会社 | 多能性幹細胞製造システム |
| WO2022244670A1 (ja) * | 2021-05-18 | 2022-11-24 | 国立大学法人京都大学 | 多能性幹細胞の製造方法 |
| CN113265333A (zh) * | 2021-06-23 | 2021-08-17 | 无锡生基医药科技有限公司 | 一种全封闭、半自动化控制、模块化的质粒瞬时转染系统 |
| WO2023034720A1 (en) * | 2021-08-28 | 2023-03-09 | Cornell University | Compositions and methods for cell reprogramming |
| WO2023053220A1 (ja) * | 2021-09-28 | 2023-04-06 | 公益財団法人京都大学ｉＰＳ細胞研究財団 | 多能性幹細胞の製造方法 |
| US20230130734A1 (en) * | 2021-10-27 | 2023-04-27 | Regenerative Research Foundation | Cell culture feeding device |
| JP2024085747A (ja) * | 2022-12-15 | 2024-06-27 | ヤマハ発動機株式会社 | 組換えタンパク質産生細胞の培養方法 |
| WO2024176440A1 (ja) * | 2023-02-24 | 2024-08-29 | 公益財団法人京都大学ｉＰＳ細胞研究財団 | 人工多能性幹細胞の製造方法 |
| CN116426573A (zh) * | 2023-04-14 | 2023-07-14 | 臻赫医药(杭州)有限公司 | 重编程因子抗衰老表达系统、生物材料及用途 |
| JP7721836B1 (ja) * | 2023-12-04 | 2025-08-12 | 公益財団法人京都大学ｉＰＳ細胞研究財団 | 人工多能性幹細胞の製造方法 |
| CN118460359B (zh) * | 2024-07-10 | 2024-09-20 | 江苏颐泽生物科技有限公司 | 一种具有细胞活性检测功能的干细胞贮存装置 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005521405A (ja) | 2002-03-28 | 2005-07-21 | ブラスティコン ビオテクノロギッシュ フォーシュング ゲーエムベーハー | 単球を起源に持つ、脱分化したプログラム可能な幹細胞およびそれらの製造と使用 |
| WO2009096614A1 (en) | 2008-01-30 | 2009-08-06 | Mirae Biotech Co., Ltd. | Method of manufacturing induced pluripotent stem cell originated from somatic cell |
| JP2012528599A (ja) | 2009-06-05 | 2012-11-15 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | リプログラミングｔ細胞および造血細胞 |
| WO2014017513A1 (ja) | 2012-07-24 | 2014-01-30 | 日産化学工業株式会社 | 培地組成物及び当該組成物を用いた細胞又は組織の培養方法 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3788026T2 (de) * | 1986-08-27 | 1994-04-21 | Kawasumi Lab Inc | Verfahren und Vorrichtung zur Kultivierung von Zellen. |
| US5399493A (en) | 1989-06-15 | 1995-03-21 | The Regents Of The University Of Michigan | Methods and compositions for the optimization of human hematopoietic progenitor cell cultures |
| CA2183638C (en) * | 1995-03-20 | 2001-03-20 | Tajima Hideji | Liquid processing method making use of pipette device and apparatus for same |
| JP3837165B2 (ja) | 1996-08-16 | 2006-10-25 | アマーシャム バイオサイエンセズ ナイアガラ，インク． | ウェルプレート、ゲル及びブロットにおける検査用のディジタルイメージングシステム |
| JP4309815B2 (ja) | 2004-07-05 | 2009-08-05 | 株式会社日立製作所 | 細胞培養システム及び細胞培養方法 |
| WO2006071716A2 (en) | 2004-12-29 | 2006-07-06 | Biogen Idec Ma Inc. | Bioreactor process control system and method |
| CN100335612C (zh) * | 2005-01-20 | 2007-09-05 | 上海交通大学 | 植物细胞或组织两段连续培养系统 |
| CN1664545A (zh) * | 2005-03-18 | 2005-09-07 | 宁波美生医疗器材有限公司 | 一种细胞薄层涂片的制作方法 |
| JP2007000038A (ja) | 2005-06-22 | 2007-01-11 | Toray Ind Inc | 閉鎖系循環回路型培養装置 |
| CN2841667Y (zh) * | 2005-09-09 | 2006-11-29 | 刘平 | 细胞滤过器 |
| US20070087437A1 (en) * | 2005-10-14 | 2007-04-19 | Jifan Hu | Methods for rejuvenating cells in vitro and in vivo |
| WO2007069666A1 (ja) | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
| JP2010526530A (ja) * | 2007-05-04 | 2010-08-05 | スンドストローム，エリック | スライシングデバイス |
| JP2008307007A (ja) * | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| DK2173863T3 (en) | 2007-06-29 | 2019-01-21 | Fujifilm Cellular Dynamics Inc | Automated method and apparatus for embryonic stem cell culture |
| US7858371B2 (en) * | 2007-09-26 | 2010-12-28 | Weyerhaeuser Nr Company | Method of separating embryo suspension mass |
| US9683232B2 (en) * | 2007-12-10 | 2017-06-20 | Kyoto University | Efficient method for nuclear reprogramming |
| EP2238236B1 (fr) * | 2008-01-09 | 2017-03-29 | Screencell | Dispositif et procédé pour isoler et cultiver des cellules vivantes sur filtre ou extraire leur matériel génétique |
| EP2315829B1 (en) * | 2008-08-08 | 2015-02-11 | Mayo Foundation For Medical Education And Research | Induced pluripotent stem cells |
| ES2561949T3 (es) * | 2008-11-21 | 2016-03-01 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Reprogramación de células hacia un estado pluripotente |
| US20120196358A1 (en) | 2009-06-01 | 2012-08-02 | Fred Burbank | Device for removing cumulus from oocytes |
| EP2486119B1 (en) | 2009-10-09 | 2017-04-19 | Georgia Tech Research Corporation | Method and device for dispersion of assemblies of biological material |
| US9018010B2 (en) * | 2009-11-12 | 2015-04-28 | Technion Research & Development Foundation Limited | Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state |
| EP2528687B1 (en) * | 2010-01-29 | 2018-08-22 | Micronics, Inc. | System comprising a host instrument and a microfluidic cartridge for assays |
| CA3122219A1 (en) * | 2010-04-16 | 2011-10-20 | The Children's Hospital Corporation | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
| EP2603517B1 (en) * | 2010-05-12 | 2023-07-19 | Cellectis | Dynamic mixing and electroporation chamber and system |
| US8048675B1 (en) * | 2010-05-12 | 2011-11-01 | Ipierian, Inc. | Integration-free human induced pluripotent stem cells from blood |
| SG10201509953VA (en) * | 2010-09-07 | 2016-01-28 | Technion Res & Dev Foundation | Novel Methods And Culture Media For Culturing Pluripotent Stem Cells |
| US20160272934A1 (en) * | 2010-10-08 | 2016-09-22 | Cellanyx Diagnostics, Llc | Systems, devices and methods for microfluidic culturing, manipulation and analysis of tissues and cells |
| CN102559587A (zh) * | 2010-12-16 | 2012-07-11 | 中国科学院上海药物研究所 | 诱导性多能干细胞的制备方法以及用于制备诱导性多能干细胞的培养基 |
| KR20140063501A (ko) * | 2010-12-22 | 2014-05-27 | 페이트 세러퓨틱스, 인코포레이티드 | 단세포 분류 및 iPSC의 증강된 재프로그래밍을 위한 세포 배양 플랫폼 |
| CN102174395B (zh) | 2011-01-30 | 2013-08-21 | 中国科学院广州生物医药与健康研究院 | 诱导多能干细胞自动化扩增与培养系统 |
| WO2012115153A1 (ja) | 2011-02-25 | 2012-08-30 | 株式会社ニコン | 細胞評価方法、細胞培養方法、細胞評価装置、インキュベータ、細胞評価プログラム、コロニー分類プログラム、幹細胞の培養方法、幹細胞評価装置および幹細胞評価プログラム |
| GB201105413D0 (en) * | 2011-03-30 | 2011-05-11 | Cambridge Entpr Ltd | Nuclear reprogramming substrate |
| US9880084B2 (en) * | 2011-04-15 | 2018-01-30 | The University Of British Columbia | Apparatus for separation of particles |
| PT2768942T (pt) * | 2011-10-17 | 2020-01-21 | Massachusetts Inst Technology | Entrega intracelular |
| WO2013058403A1 (ja) | 2011-10-21 | 2013-04-25 | 国立大学法人京都大学 | 層流による多能性維持単一分散細胞培養法 |
| EP2594632A1 (en) * | 2011-11-18 | 2013-05-22 | Miltenyi Biotec GmbH | Method and device for cell modification |
| US20140329317A1 (en) * | 2011-11-25 | 2014-11-06 | Kyoto University | Method for culturing pluripotent stem cell |
| US10428309B2 (en) * | 2011-12-01 | 2019-10-01 | New York Stem Cell Foundation, Inc. | Systems and methods for producing stem cells and differentiated cells |
| ES3038941T3 (en) * | 2011-12-01 | 2025-10-16 | New York Stem Cell Found Inc | Automated system for producing induced pluripotent stem cells or differentiated cells |
| BR112014014405A2 (pt) * | 2011-12-15 | 2017-06-13 | Dow Agrosciences Llc | método para transformação aperfeiçoada usando agrobacterium |
| JP5274731B1 (ja) | 2011-12-22 | 2013-08-28 | 三洋電機株式会社 | 観察システム、プログラム及び観察システムの制御方法 |
| WO2013136372A1 (ja) | 2012-03-16 | 2013-09-19 | 株式会社日立製作所 | 細胞シート、細胞培養方法および細胞培養装置 |
| WO2013177228A1 (en) * | 2012-05-22 | 2013-11-28 | Loma Linda University | Generation of integration/transgene-free stem cells |
| EP2861612A4 (en) * | 2012-06-13 | 2016-02-17 | Stemgent Inc | METHOD FOR PRODUCING PLURIPOTENT STEM CELLS |
| US9664671B2 (en) * | 2012-07-24 | 2017-05-30 | Nissan Chemical Industries, Ltd. | Culture medium composition and method of culturing cell or tissue using thereof |
| TR201809547T4 (tr) * | 2012-11-09 | 2018-07-23 | Biontech Rna Pharmaceuticals Gmbh | Hücresel RNA ifadesine yönelik yöntem. |
| WO2014136581A1 (ja) | 2013-03-06 | 2014-09-12 | 国立大学法人京都大学 | 多能性幹細胞の培養システム及び多能性幹細胞の継代方法 |
| WO2014153069A2 (en) * | 2013-03-14 | 2014-09-25 | Children's Medical Center Corporation | Compositions and methods for reprogramming hematopoietic stem cell lineages |
| SG11201504876TA (en) * | 2013-03-15 | 2015-07-30 | Fluidigm Corp | Methods and devices for analysis of defined multicellular combinations |
| WO2014148646A1 (ja) | 2013-03-21 | 2014-09-25 | 国立大学法人京都大学 | 神経分化誘導用の多能性幹細胞 |
| US20160060601A1 (en) * | 2013-04-17 | 2016-03-03 | Nissan Chemical Industries, Ltd. | Medium composition and method for producing red blood cells using same |
| US20150159127A1 (en) * | 2013-05-10 | 2015-06-11 | BioCapacity On Demand, LLC | Mobile vessel or carrier for the manufacturing production, purification and sterile fill and finish of biologics |
| WO2014200114A1 (en) * | 2013-06-11 | 2014-12-18 | Kyoto University | Method of efficiently establishing induced pluripotent stem cells |
| US9580678B2 (en) * | 2013-06-21 | 2017-02-28 | The Regents Of The University Of California | Microfluidic tumor tissue dissociation device |
| EP3569699A1 (en) | 2013-09-04 | 2019-11-20 | Otsuka Pharmaceutical Factory, Inc. | Method for preparing pluripotent stem cells |
| JP5751726B2 (ja) | 2013-11-12 | 2015-07-22 | 東京エレクトロン株式会社 | 多能性幹細胞の培養方法及び施設 |
| SG11201606056RA (en) | 2014-01-23 | 2016-08-30 | Nissan Chemical Ind Ltd | Culture medium composition |
| KR102282265B1 (ko) | 2014-01-23 | 2021-07-26 | 닛산 가가쿠 가부시키가이샤 | 배양 배지 조성물의 제조 방법 |
| US10100286B2 (en) * | 2014-06-20 | 2018-10-16 | The Board Of Trustees Of The University Of Alabama | Systems and methods of dissociating aggregate spheres of cells |
| WO2016090237A1 (en) * | 2014-12-04 | 2016-06-09 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Systems for dissociation of biological tissues |
| JP6291429B2 (ja) | 2015-01-20 | 2018-03-14 | 富士フイルム株式会社 | 細胞培養装置および細胞培養方法 |
| EP3247808B1 (en) * | 2015-01-21 | 2021-05-05 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
| US10836997B2 (en) | 2015-03-09 | 2020-11-17 | Keio University | Method for differentiating pluripotent stem cells into desired cell type |
| CN114717183B (zh) | 2015-08-31 | 2024-11-29 | 爱平世股份有限公司 | 多能干细胞制造系统和生产诱导多能干细胞的方法 |
| KR102802007B1 (ko) * | 2016-06-08 | 2025-04-28 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 조직 및 세포를 프로세싱하기 위한 방법 및 장치 |
-
2016
- 2016-08-30 CN CN202210349694.4A patent/CN114717183B/zh active Active
- 2016-08-30 WO PCT/US2016/049530 patent/WO2017040548A1/en not_active Ceased
- 2016-08-30 CN CN201680050145.XA patent/CN108138130A/zh active Pending
- 2016-08-30 US US15/756,029 patent/US11286454B2/en active Active
- 2016-08-30 JP JP2018510722A patent/JP7370529B2/ja active Active
- 2016-08-30 EP EP16842835.7A patent/EP3344755A4/en active Pending
- 2016-08-30 CA CA2996582A patent/CA2996582A1/en active Pending
- 2016-08-31 EP EP18203880.2A patent/EP3473703A3/en not_active Withdrawn
- 2016-08-31 SG SG11201801549VA patent/SG11201801549VA/en unknown
- 2016-08-31 CN CN202211151066.1A patent/CN115478045A/zh active Pending
- 2016-08-31 CA CA2996988A patent/CA2996988A1/en active Pending
- 2016-08-31 WO PCT/JP2016/075540 patent/WO2017038887A1/ja not_active Ceased
- 2016-08-31 EP EP18167250.2A patent/EP3366763B1/en active Active
- 2016-08-31 CN CN201810580097.6A patent/CN108823062B/zh not_active Expired - Fee Related
- 2016-08-31 EP EP16841917.4A patent/EP3345990A4/en active Pending
- 2016-08-31 CN CN201680050144.5A patent/CN108138113A/zh active Pending
- 2016-08-31 JP JP2017526727A patent/JP6198203B2/ja active Active
- 2016-08-31 US US15/756,031 patent/US11518974B2/en active Active
-
2017
- 2017-05-16 JP JP2017097398A patent/JP6283904B2/ja active Active
- 2017-05-16 JP JP2017097408A patent/JP2017221187A/ja active Pending
- 2017-08-10 JP JP2017155756A patent/JP6253216B2/ja active Active
-
2019
- 2019-03-11 US US16/299,048 patent/US10508260B2/en active Active
- 2019-11-14 JP JP2019206125A patent/JP7351483B2/ja active Active
-
2022
- 2022-01-06 US US17/569,634 patent/US20220119758A1/en not_active Abandoned
- 2022-04-06 JP JP2022063287A patent/JP2022088643A/ja active Pending
- 2022-08-03 US US17/817,287 patent/US11912977B2/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005521405A (ja) | 2002-03-28 | 2005-07-21 | ブラスティコン ビオテクノロギッシュ フォーシュング ゲーエムベーハー | 単球を起源に持つ、脱分化したプログラム可能な幹細胞およびそれらの製造と使用 |
| WO2009096614A1 (en) | 2008-01-30 | 2009-08-06 | Mirae Biotech Co., Ltd. | Method of manufacturing induced pluripotent stem cell originated from somatic cell |
| JP2012528599A (ja) | 2009-06-05 | 2012-11-15 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | リプログラミングｔ細胞および造血細胞 |
| WO2014017513A1 (ja) | 2012-07-24 | 2014-01-30 | 日産化学工業株式会社 | 培地組成物及び当該組成物を用いた細胞又は組織の培養方法 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7351483B2 (ja) | 多能性幹細胞製造システム、幹細胞の誘導方法、幹細胞の浮遊培養方法、幹細胞の浮遊培養器、人工多能性幹細胞の作製方法、及び動物細胞から特定の体細胞を作製する方法 | |
| JP7732645B2 (ja) | 細胞の培養又は誘導方法 | |
| JP7146211B2 (ja) | 人工多能性幹細胞の作製方法 | |
| EP2970913B1 (en) | Cells, methods and apparatuses for umbilical cord blood collection and isolation of cells | |
| JP2016509863A5 (enExample) | ||
| JP2023011942A (ja) | 神経系細胞の作製方法 | |
| JP2020036608A (ja) | 多能性幹細胞製造システム、幹細胞の誘導方法、幹細胞の浮遊培養方法、幹細胞の浮遊培養器、人工多能性幹細胞の作製方法、及び動物細胞から特定の体細胞を作製する方法 | |
| JP2022104813A (ja) | リプログラミング因子を導入された細胞の培養方法 | |
| HK40067121B (zh) | 多能干细胞制造系统和生产诱导多能干细胞的方法 | |
| HK40067121A (en) | Pluripotent stem cell manufacturing system and method for producing induced pluripotent stem cells | |
| JP7758307B2 (ja) | 幹細胞の製造方法 | |
| HK40043180A (zh) | 细胞的培养或诱导方法 | |
| HK40011227A (en) | Production method for artificial pluripotent stem cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190522 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190523 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190823 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190823 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20191024 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20191024 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200928 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201222 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210520 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210813 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20211206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220406 |
|
| C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20220406 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20220413 |
|
| C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20220414 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20220513 |
|
| C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20220517 |
|
| C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20230405 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230823 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231010 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7370529 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |